Download PDF
Semin Thromb Hemost 2012; 38(07): 711-719
DOI: 10.1055/s-0032-1326783
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Approach to the Diagnosis and Management of Common Bleeding Disorders

Natalia Rydz
1   Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
,
Paula D. James
2   Division of Hematology, Queen's University, Kingston, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
01 September 2012 (online)

    Permissions and Reprints

Abstract

Mild mucocutaneous bleeding symptoms are common in the general population. Differentiating normal from pathological bleeding complaints begins with a detailed bleeding history that assesses: the pattern (primary versus secondary hemostasis), the severity, and the onset (congenital versus acquired) of bleeding. Bleeding assessment tools have been developed to aid in determining whether bleeding symptoms are outside of the normal range. Although the clinical pattern of bleeding and family history directs laboratory investigations, von Willebrand disease, the most common and best characterized of the primary hemostatic disorders, is often the first diagnosis to be considered. Clinical management focuses on the particular symptoms experienced by the patient. Medical interventions include replacement of the factor that is deficient or defective, or indirect treatments, such as antifibrinolytics (tranexamic acid), desmopression, and hormone-based therapy (e.g., oral contraceptive pill for menorrhagia).

Keywords

mucocutaneous bleeding - bleeding scores - bruising - epistaxis - menorrhagia - von Willebrand disease - hemophilia - platelet function disorder
 

  • References

  • 1 Silwer J. von Willebrand's disease in Sweden. Acta Paediatr Scand Suppl 1973; 238: 1-159
    PubMedGoogle Scholar
  • 2 Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111 (4) 1236-1239
    CrossrefPubMedGoogle Scholar
  • 3 Rodeghiero F, Castaman G, Tosetto A , et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005; 3 (12) 2619-2626
    CrossrefPubMedGoogle Scholar
  • 4 Srámek A, Eikenboom JC, Briët E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Intern Med 1995; 155 (13) 1409-1415
    CrossrefPubMedGoogle Scholar
  • 5 Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia 2004; 10 (Suppl 4) 169-176
    PubMedGoogle Scholar
  • 6 Favaloro EJ. Rethinking the diagnosis of von Willebrand disease. Thromb Res 2011; 127 (Suppl 2) S17-S21
    PubMedGoogle Scholar
  • 7 Hayward CPM. Diagnostic evaluation of platelet function disorders. Blood Rev 2011; 25 (4) 169-173
    CrossrefPubMedGoogle Scholar
  • 8 Quiroga T, Goycoolea M, Panes O , et al. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica 2007; 92 (3) 357-365
    CrossrefPubMedGoogle Scholar
  • 9 Warner PE, Critchley HOD, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol 2004; 190 (5) 1216-1223
    CrossrefPubMedGoogle Scholar
  • 10 Philipp CS, Faiz A, Dowling NF , et al. Development of a screening tool for identifying women with menorrhagia for hemostatic evaluation. Am J Obstet Gynecol 2008; 198 (2) 163 , e1–e8
    PubMedGoogle Scholar
  • 11 Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001; 286 (2) 208-216
    CrossrefPubMedGoogle Scholar
  • 12 Nosek-Cenkowska B, Cheang MS, Pizzi NJ, Israels ED, Gerrard JM. Bleeding/bruising symptomatology in children with and without bleeding disorders. Thromb Haemost 1991; 65 (3) 237-241
    PubMedGoogle Scholar
  • 13 Drews CD, Dilley AB, Lally C, Beckman MG, Evatt B. Screening questions to identify women with von Willebrand disease. J Am Med Womens Assoc 2002; 57 (4) 217-218
    PubMedGoogle Scholar
  • 14 Tosetto A, Rodeghiero F, Castaman G , et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4 (4) 766-773
    CrossrefPubMedGoogle Scholar
  • 15 Federici AB, Mannucci PM, Castaman G , et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113 (3) 526-534
    CrossrefPubMedGoogle Scholar
  • 16 Biss TT, Blanchette VS, Clark DS , et al. Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire. J Thromb Haemost 2010; 8 (5) 950-956
    PubMedGoogle Scholar
  • 17 Biss TT, Blanchette VS, Clark DS, Wakefield CD, James PD, Rand ML. Use of a quantitative pediatric bleeding questionnaire to assess mucocutaneous bleeding symptoms in children with a platelet function disorder. J Thromb Haemost 2010; 8 (6) 1416-1419
    CrossrefPubMedGoogle Scholar
  • 18 Bowman M, Mundell G, Grabell J , et al. Generation and validation of the condensed MCMDM-1VWD bleeding questionnaire for von Willebrand disease. J Thromb Haemost 2008; 6 (12) 2062-2066
    CrossrefPubMedGoogle Scholar
  • 19 Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost 2009; 7 (8) 1418-1421
    CrossrefPubMedGoogle Scholar
  • 20 Marcus PD, Nire KG, Grooms L, Klima J, O'Brien SH. The power of a standardized bleeding score in diagnosing paediatric type 1 von Willebrand's disease and platelet function defects. Haemophilia 2011; 17 (2) 223-227
    CrossrefPubMedGoogle Scholar
  • 21 Tosetto A, Castaman G, Plug I, Rodeghiero F, Eikenboom J. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost 2011; 9 (6) 1143-1148
    CrossrefPubMedGoogle Scholar
  • 22 Rodeghiero F, Tosetto A, Abshire T , et al; ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8 (9) 2063-2065
    CrossrefPubMedGoogle Scholar
  • 23 Mauer AC, Barbour EM, Khazanov NA, Levenkova N, Mollah SA, Coller BS. Creating an ontology-based human phenotyping system: The Rockefeller University bleeding history experience. Clin Transl Sci 2009; 2 (5) 382-385
    CrossrefPubMedGoogle Scholar
  • 24 Mauer AC, Khazanov NA, Levenkova N , et al. Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost 2011; 9 (1) 100-108
    CrossrefPubMedGoogle Scholar
  • 25 Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97 (8) 734-739
    CrossrefPubMedGoogle Scholar
  • 26 Philipp CS, Faiz A, Heit JA , et al. Evaluation of a screening tool for bleeding disorders in a US multisite cohort of women with menorrhagia. Am J Obstet Gynecol 2011; 204 (3) 209 , e1–e7
    PubMedGoogle Scholar
  • 27 McKay H, Derome F, Haq MA , et al. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 2004; 104 (1) 159-165
    CrossrefPubMedGoogle Scholar
  • 28 Beighton P, Solomon L, Soskolne CL. Articular mobility in an African population. Ann Rheum Dis 1973; 32 (5) 413-418
    CrossrefPubMedGoogle Scholar
  • 29 Mishra P, Naithani R, Dolai T , et al. Intracranial haemorrhage in patients with congenital haemostatic defects. Haemophilia 2008; 14 (5) 952-955
    CrossrefPubMedGoogle Scholar
  • 30 Malfait F, De Paepe A. Bleeding in the heritable connective tissue disorders: mechanisms, diagnosis and treatment. Blood Rev 2009; 23 (5) 191-197
    CrossrefPubMedGoogle Scholar
  • 31 Mehta R, Shapiro AD. Plasminogen activator inhibitor type 1 deficiency. Haemophilia 2008; 14 (6) 1255-1260
    CrossrefPubMedGoogle Scholar
  • 32 Carpenter SL, Mathew P. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia 2008; 14 (6) 1250-1254
    CrossrefPubMedGoogle Scholar
  • 33 Podda GM, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost 2007; 5 (12) 2393-2398
    CrossrefPubMedGoogle Scholar
  • 34 Quiroga T, Goycoolea M, Muñoz B , et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost 2004; 2 (6) 892-898
    CrossrefPubMedGoogle Scholar
  • 35 Castaman G, Tosetto A, Goodeve A , et al. The impact of bleeding history, von Willebrand factor and PFA-100(®) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD. Br J Haematol 2010; 151 (3) 245-251
    CrossrefPubMedGoogle Scholar
  • 36 Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK ; Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4 (2) 312-319
    CrossrefPubMedGoogle Scholar
  • 37 Hayward CPM, Pai M, Liu Y , et al. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost 2009; 7 (4) 676-684
    CrossrefPubMedGoogle Scholar
  • 38 Hayward CPM, Moffat KA, Raby A , et al. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol 2010; 134 (6) 955-963
    CrossrefPubMedGoogle Scholar
  • 39 Nieuwenhuis HK, Akkerman JW, Sixma JJ. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood 1987; 70 (3) 620-623
    PubMedGoogle Scholar
  • 40 Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 1991; 325 (3) 153-158
    CrossrefPubMedGoogle Scholar
  • 41 Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia 2008; 14 (6) 1190-1200
    CrossrefPubMedGoogle Scholar
  • 42 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69 (2) 454-459
    PubMedGoogle Scholar
  • 43 Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123 (6) 893-898
    CrossrefPubMedGoogle Scholar
  • 44 Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost 2010; 8 (1) 213-216
    CrossrefPubMedGoogle Scholar
  • 45 Sadler JE, Budde U, Eikenboom JCJ , et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
    CrossrefPubMedGoogle Scholar
  • 46 Stine KC, Becton DL. DDAVP therapy controls bleeding in Ehlers-Danlos syndrome. J Pediatr Hematol Oncol 1997; 19 (2) 156-158
    CrossrefPubMedGoogle Scholar
  • 47 De Paepe A, Malfait F. Bleeding and bruising in patients with Ehlers-Danlos syndrome and other collagen vascular disorders. Br J Haematol 2004; 127 (5) 491-500
    CrossrefPubMedGoogle Scholar
  • 48 Nurden P, Nurden AT. Congenital disorders associated with platelet dysfunctions. Thromb Haemost 2008; 99 (2) 253-263
    PubMedGoogle Scholar
  • 49 Mannucci PM, Tuddenham EGD. The hemophilias—from royal genes to gene therapy. N Engl J Med 2001; 344 (23) 1773-1779
    CrossrefPubMedGoogle Scholar
  • 50 Pavlova A, Brondke H, Müsebeck J, Pollmann H, Srivastava A, Oldenburg J. Molecular mechanisms underlying hemophilia A phenotype in seven females. J Thromb Haemost 2009; 7 (6) 976-982
    CrossrefPubMedGoogle Scholar
  • 51 Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104 (5) 1243-1252
    CrossrefPubMedGoogle Scholar
  • 52 Acharya SS, Coughlin A, Dimichele DM ; North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2 (2) 248-256
    CrossrefPubMedGoogle Scholar
  • 53 Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008; 112 (2) 250-255
    CrossrefPubMedGoogle Scholar
  • 54 Mohri H, Motomura S, Kanamori H , et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998; 91 (10) 3623-3629
    PubMedGoogle Scholar
  • 55 Vincentelli A, Susen S, Le Tourneau T , et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349 (4) 343-349
    CrossrefPubMedGoogle Scholar
  • 56 Uriel N, Pak S-W, Jorde UP , et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 2010; 56 (15) 1207-1213
    CrossrefPubMedGoogle Scholar
  • 57 Meyer AL, Malehsa D, Bara C , et al. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail 2010; 3 (6) 675-681
    CrossrefPubMedGoogle Scholar
  • 58 Federici AB, Rand JH, Bucciarelli P , et al; Subcommittee on von Willebrand Factor. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84 (2) 345-349
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011; 117 (25) 6777-6785
    CrossrefPubMedGoogle Scholar
  • 60 Nichols WL, Rick ME, Ortel TL , et al. Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol 2009; 84 (6) 366-370
    CrossrefPubMedGoogle Scholar
  • 61 James AH, Kouides PA, Abdul-Kadir R , et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol 2009; 201 (1) 12 , e1–e8
    PubMedGoogle Scholar
  • 62 Santagostino E, Mannucci PM, Bianchi Bonomi A. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 2000; 6 (1) 1-10
    PubMedGoogle Scholar
  • 63 Nichols WL, Hultin MB, James AH , et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (2) 171-232
    CrossrefPubMedGoogle Scholar
  • 64 Ansell J, Hirsh J, Hylek E , et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 381S-453S
    CrossrefPubMedGoogle Scholar
  • 65 Galbusera M, Remuzzi G, Boccardo P. Treatment of bleeding in dialysis patients. Semin Dial 2009; 22 (3) 279-286
    CrossrefPubMedGoogle Scholar
  • 66 Federici AB. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977–2007). Haemophilia 2008; 14 (Suppl 1) 5-14
    PubMedGoogle Scholar
  • 67 Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A. Blood Coagul Fibrinolysis 2010; 21 (7) 615-619
    PubMedGoogle Scholar
  • 68 Bolton-Maggs PHB, Chalmers EA, Collins PW , et al; UKHCDO. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006; 135 (5) 603-633
    CrossrefPubMedGoogle Scholar
  • 69 Franchini M, Manzato F, Salvagno GL, Montagnana M, Lippi G. The use of desmopressin in congenital factor XI deficiency: a systematic review. Ann Hematol 2009; 88 (10) 931-935
    CrossrefPubMedGoogle Scholar
  • 70 Edlund M, Blombäck M, Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time. Blood Coagul Fibrinolysis 2002; 13 (3) 225-231
    CrossrefPubMedGoogle Scholar
  • 71 Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane database of systematic reviews (Online). 2000 ;CD000249.
    PubMedGoogle Scholar
  • 72 Ageno W, Gallus AS, Wittkowsky A , et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e44S-88S
    CrossrefPubMedGoogle Scholar